Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TG4040 + pegylated interferon + ribavirin
- Development stage
- Unknown
- Lead developer
- Transgene
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
TG4040 + pegylated interferon + ribavirin is a **three-drug combination** developed for the treatment of chronic hepatitis C virus (HCV) infection. TG4040 is a therapeutic vaccine based on a recombinant Modified Vaccinia Ankara (MVA) viral vector encoding the NS3, NS4, and NS5B antigens of HCV, designed to induce a strong and broad T-cell immune response against HCV. Pegylated interferon (peginterferon alfa-2a or alfa-2b) is a long-acting form of interferon with antiviral and immunomodulatory effects, while ribavirin is a nucleoside analog that enhances viral clearance when used with interferon. This combination therapy aims to boost the host's immune response against HCV (via TG4040) and enhance viral elimination with standard antiviral agents (pegylated interferon + ribavirin). Preclinical and clinical phase 2 data have been published for this triple therapy.
- Other names
- HCV therapeutic vaccine - TransgeneHepatitis C vaccine - Transgene
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)NS3 (Dengue virus NS3 protein)CDKN1B (Transmembrane emp24 domain-containing protein 7)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on TG4040 + pegylated interferon + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TG4040 + pegylated interferon + ribavirin.